MS researchers find decline in cognitive performance for people with multiple sclerosis as outdoor temperatures rise

 

Results have implications for patients and researchers

 

West Orange, N.J. (March 13, 2012) – Kessler Foundation scientists have shown for the first time that outdoor temperature significantly affects cognitive functioning in multiple sclerosis (MS). While it is recognized that disease activity increases during warmer months, this is the first study to document that cognition also fluctuates. During warmer outdoor temperatures patients with MS performed worse on tasks involving processing speed and memory. An estimated 50 to 65% of people with MS experience problems with thinking, learning and remembering that can be disabling.

 

Warmer outdoor temperature is associated with worse cognitive status in MS,” was published online ahead of print by Neurology. An accompanying editorial, “MS and heat: The smoke and the fire,” discusses the study’s contributions to understanding MS. According to the results, cognitive performance may be a more sensitive indicator of subclinical disease activity than traditional assessments.

 

In the study, which spanned the calendar year, 40 individuals with MS and 40 people without MS underwent cognitive assessment of memory and processing speed. People with MS scored 70 percent higher on cooler days; no association was found for individuals without MS. Funding was provided by the National MS Society and the NIH.

 

According to Victoria M. Leavitt, Ph.D., research scientist, and the study’s principal investigator, these findings have implications for patients, clinicians and researchers. “This information is relevant to making life decisions and choosing therapies and evaluating their effects,” said Dr. Leavitt. “Outdoor temperatures may be an important consideration when designing and conducting clinical trials, many of which span six months.” For example, taking baseline measurements during warmer months could inflate positive findings. The study’s co-investigators are James F. Sumowski, Ph.D., Research Scientist, Nancy Chiaravalloti, Ph.D., Director of Neuropsychology & Neuroscience Research, and John DeLuca, Ph.D., VP for Research.

 

Kessler Foundation is nationally and internationally known for cognitive rehabilitation research in MS and traumatic brain injury. Its neuroscience research supports the theory of cognitive reserve, ie, people with MS who lead intellectually enriching lives are less likely to experience cognitive decline. A recent publication documented changes in brain activity on fMRI associated with effective memory retraining in people with MS.

 

 

About Kessler Foundation

 

Kessler Foundation, the largest public charity in the field of disability, conducts rehabilitation research in mobility and cognition that advances the care of people with multiple sclerosis, brain injury, stroke and spinal cord injury. Kessler Foundation Program Center fosters new approaches to the persistently high rates of unemployment among people disabled by injury or disease.  

 


Kessler Foundation, 13.03.2012 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…